Asio Capital LLC Reduces Stake in IQVIA Holdings Inc.

Asio Capital LLC has made significant changes to its investments in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter. According to the latest Form 13F filing with the Securities and Exchange Commission, Asio Capital reduced its position in IQVIA shares by an impressive 59.2%. This reduction resulted in the fund holding 4,304 shares after selling 6,233 shares throughout the reporting period. By the end of this reporting period, Asio Capital’s holdings in IQVIA were valued at approximately $846,000.

Other institutional investors have also recently adjusted their holdings in IQVIA. For instance, Capital Performance Advisors LLP made a new investment in IQVIA during the third quarter, amounting to around $27,000. Similarly, Park Place Capital Corp acquired a new stake in the company's shares in the same quarter, valued at $28,000. Furthermore, Avior Wealth Management LLC increased its holdings by a remarkable 117.6% during the third quarter, bringing its total to 161 shares, valued at $38,000 following the addition of 87 shares.

Additionally, Assetmark Inc. raised its stake in IQVIA significantly by 612.5% in the third quarter. After purchasing an extra 196 shares, Assetmark now holds 228 shares worth $54,000. UMB Bank n.a. also strengthened its position in IQVIA by 74.4% during the previous quarter, leading to ownership of 232 shares valued at $55,000. Collectively, institutional investors currently own approximately 89.62% of IQVIA’s stock.

IQVIA Price Performance

As for the stock's price performance, IQVIA shares opened at $204.54 recently. The company has a 50-day simple moving average of $199.71 and a 200-day simple moving average of $221.06. IQVIA Holdings shows a fifty-two week low of $187.62 and a high of $261.73. The company boasts a market capitalization of $37.12 billion, with a price-to-earnings ratio (P/E) of 26.84, and a price-to-earnings-to-growth (P/E/G) ratio of 2.14. Other financial metrics include a beta of 1.48, a debt-to-equity ratio of 1.76, along with both a quick ratio and current ratio of 0.81.

Analyst Upgrades and Downgrades

Several analysts have recently commented on IQVIA shares. For example, Leerink Partners has reaffirmed an "outperform" rating and adjusted its price target for IQVIA shares to $248.00, down from a previous target of $260.00 in a report dated November 19th. StockNews.com has also revised its rating, lowering IQVIA shares from a "buy" to a "hold" on November 28th. Deutsche Bank Aktiengesellschaft set a new price objective of $265.00 for IQVIA shares, down from $270.00, while maintaining a "buy" stance in a report dated November 1st. The Goldman Sachs Group lowered their target price from $280.00 to $250.00 and reiterated a "buy" rating. Lastly, Barclays adjusted its price target from $260.00 to $255.00 with an "overweight" rating. Overall, four analysts have given the stock a hold rating, while seventeen have rated it a buy, leading to a collective average rating of "Moderate Buy" at an average price target of $255.71.

About IQVIA

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry across various regions including the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three distinct segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Investment, Stocks, Shares